CD8A and neoplasm: Although PLK1345/9M and Ova55DC_TriVax had moderate therapeutic effects when compared to unvaccinated mice, mice that received PLK1122DC_TriVax vaccination had substantially reduced tumour progression as compared to those with PKL1345/9M and Ova55 peptides, marked by significantly lower bioluminescent signals (by day42), which correlated with the observed tumour growth (5 out of 6 mice completely rejected; Fig. 1d, e) and the levels of antigen-specific CD8 T-cells observed in blood (Fig. 1f).